blu0588 Search Results


blu0588  (MedChemExpress)
94
MedChemExpress blu0588
(A) Assessment of synergy in Cal27 cells treated with a combination of metformin and <t>BLU0588</t> (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.
Blu0588, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blu0588/BLU0588/pmc12826122-43-0-6
Average 94 stars, based on 1 article reviews
blu0588 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
blu0588  (MuseChem Chemicals)
N/A
BLU0588(CAT: I040908) is an orally active, potent, and selective inhibitor of PRKACA (protein kinase cAMP-activated catalytic subunit alpha), with an IC50 value of 1 nM and a dissociation constant (Kd) of 4 nM. PRKACA is
   Buy from Supplier
blu0588  (TargetMol)
N/A
   Buy from Supplier

Image Search Results


(A) Assessment of synergy in Cal27 cells treated with a combination of metformin and BLU0588 (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.

Journal: Cancer prevention research (Philadelphia, Pa.)

Article Title: Genome-wide CRISPR screening reveals a PKA-driven resistance mechanism to metformin for oral cancer prevention that can be exploited by combination with NSAIDs

doi: 10.1158/1940-6207.CAPR-25-0264

Figure Lengend Snippet: (A) Assessment of synergy in Cal27 cells treated with a combination of metformin and BLU0588 (PKAi). Cell viability was measured 72 h after treatment (left). The combination index (CI) was determined using the HSA method (right). (B) Distribution of CI in a panel of HNSCC cells. CI was determined using the HSA method (CI > 10 synergism, 0 < CI < 10 additivity, CI < 0 antagonism). (C) Western blot showing p-CREB and p-PKA substrates in response to treatment with 3 mmol/L metformin, 1 μM PKAi, or 3 mmol/L metformin + 1 μM PKAi for 24 h in HNSCC cells.

Article Snippet: BLU0588 (cat. #HY-153967) was purchased from MedChemExpress.

Techniques: Inhibition, In Vitro, Western Blot